Galderma reports pediatric nemolizumab data: stock pre-market at EUR 186.65
Published on 10/16/2026 at 07:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPediatric study findings and timing
- Galderma reported pediatric nemolizumab findings on October 15, 2026, including itch-response rates of 56.00 percent to 72.00 percent at Week 16.
- Galderma stock trades pre-market at EUR 186.65 at 7:51 a.m. CEST at Lang & Schwarz on October 16, 2026.
- The results are being presented at the PeDRA Annual Conference from October 15 through October 17, 2026.
Galderma's October 15, 2026, release reported new phase II data for nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis. The company said the findings showed sustained improvements in itch, sleep disturbance and quality of life through Week 52.
Pre-market price
Galderma stock trades pre-market at EUR 186.65 at 7:51 a.m. CEST at Lang & Schwarz on October 16, 2026. The bid was EUR 185.90 and the ask was EUR 187.40. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Galderma stock.
Pediatric nemolizumab findings
The Galderma release said itch-response rates at Week 16 ranged from 56.00 percent to 72.00 percent across cohorts, while sleep-disturbance scores improved by 70.00 percent to 78.00 percent. The results are being presented at the Pediatric Dermatology Research Alliance Annual Conference, held October 15 through October 17, 2026.
What matters today: The PeDRA Annual Conference continues through October 17, 2026. A round-number reference of EUR 200.00 is 7.16 percent above the Lang & Schwarz price. Galderma's latest release reported Week 52 results for the pediatric phase II study on October 15, 2026.
Market context: Market report SMI.
